文献速递淋巴瘤

结节性淋巴细胞为主型霍奇金淋巴瘤的治疗策略

How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
PubMed 文献 · Blood · 2020-01-01

本文综述结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)的治疗选择。NLPHL 为罕见惰性淋巴瘤,肿瘤细胞 CD20 阳性而 CD30 阴性,多数初诊为早期。IA 期常用局限野放疗,其他早期及中间期多用联合模式治疗,晚期单用化疗;复发时常规化疗、抗 CD20 抗体和放疗均有效,仅高危如早期复发者考虑大剂量化疗联合自体干细胞移植。

要点

  • NLPHL 肿瘤细胞 CD20 阳性、CD30 阴性,多数病程惰性。
  • IA 期首选局限野放疗,其他早期/中间期多联合治疗,晚期单用化疗。
  • 仅早期复发等高危患者考虑大剂量化疗联合自体干细胞移植。

核心结论

  • NLPHL 总体生存极佳,相较一般人群超额死亡率低。
  • 治疗按分期分层:IA 期局限野放疗,其他早期及中间期联合模式,晚期单用化疗。
  • 复发时常规化疗、抗 CD20 抗体和放疗均为有效手段。

研究设计与样本

  • 综述类文章,基于现有数据并结合 2 例临床病例讨论治疗选择及影响因素。

主要发现

  • NLPHL 为罕见淋巴瘤,病理与临床特征独特。
  • 疾病定义性淋巴细胞为主型细胞恒定 CD20 阳性,不表达 CD30。
  • 多数病例临床过程惰性,初诊时多为早期。
  • 患者总体生存和相对生存极佳,超额死亡率低。

临床怎么用

  • IA 期 NLPHL 一线可行局限野放疗。
  • 非 IA 期早期及中间期 NLPHL 多采用联合模式治疗。
  • 晚期 NLPHL 单用化疗。
  • 复发 NLPHL 可用常规化疗、抗 CD20 抗体或放疗。
  • 仅具有早期复发等不良风险特征者考虑大剂量化疗联合自体干细胞移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical characteristics. Unlike the malignant cells in classical Hodgkin lymphoma, the disease-defining lymphocyte-predominant cells in NLPHL are consistently positive for CD20, but do not express CD30. The clinical course of NLPHL is indolent in the majority of cases. Most patients present with early-stage disease at the initial diagnosis. First-line treatment of stage IA NLPHL usually consists of limited-field radiotherapy alone. Patients with early-stage NLPHL other than stage IA and intermediate-stage disease mostly receive combined-modality treatment, whereas individuals with advanced NLPHL are treated with chemotherapy alone. In relapsed NLPHL, conventional chemotherapy, anti-CD20 antibodies, and radiotherapy represent active treatment modalities. Only patients with poor-risk characteristics such as early disease recurrence are candidates for aggressive salvage treatment with high-dose chemotherapy and autologous stem cell transplantation. The overall and relative survival of patients with NLPHL is excellent as indicated by a low excess mortality compared with the general population. This article discusses treatment options for patients with NLPHL and factors that influence the choice of therapy on the basis of the available data and 2 clinical cases.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Eichenauer DA, Engert A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2020. PMID: 32877522. doi:10.1182/blood.2019004044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。